세계의 남성형 탈모 치료 시장 : 치료 유형별, 약물 유형별, 투여 채널별, 유통 경로별, 최종 사용자별, 지역별 분석 및 예측(-2030년)

According to Stratistics MRC, the Global Androgenetic Alopecia Treatment Market is accounted for $3.0 billion in 2024 and is expected to reach $5.3 billion by 2030 growing at a CAGR of 9.6% during the forecast period. Androgenetic alopecia treatment aims to manage hair loss caused by genetic and hormonal factors, primarily affecting men and women. It encompasses various approaches, including medications like minoxidil and finasteride, which promote hair growth and prevent further loss. Surgical options like hair transplant surgery are also common, involving the relocation of healthy hair follicles to balding areas. Additionally, lifestyle changes, such as stress reduction and a balanced diet, complement these treatments for more comprehensive results in combating androgenetic alopecia.

According to The Journal of Clinical and Diagnostic Research (JCDR)'s study, roughly 60% of the population suffers from hair loss, with various factors contributing to the severity of pattern hair loss in both sexes.

Market Dynamics:

Driver:

Increasing prevalence of androgenetic alopecia

The increasing prevalence of androgenetic alopecia has significantly impacted the market. As more individuals are affected by this condition, there's a growing demand for effective treatments and solutions. This trend has spurred innovation and research within the market, leading to the development of advanced therapies and products tailored to address the specific needs of individuals experiencing androgenetic alopecia. The market's expansion reflects the rising awareness and emphasis on hair loss management and restoration.

Restraint:

Side effects and safety concerns

In the market, side effects and safety concerns pose significant challenges. Patients may experience adverse reactions such as scalp irritation, dryness, or changes in hair texture with topical medications like minoxidil. Oral medications like finasteride have raised concerns about potential sexual side effects. These challenges underscore the importance of ongoing research and development for safer, more effective treatments.

Opportunity:

Growing demand for effective treatments

The market is experiencing a significant surge in demand for effective treatments. This is driven by factors such as increasing awareness, changing lifestyle patterns, and a growing aging population. Consumers are seeking innovative solutions that can effectively address hair loss concerns, leading to a burgeoning market with opportunities for novel therapies and products to cater to this demand.

Threat:

Lack of awareness

Many individuals affected by this condition may not fully understand the options for managing or treating it, leading to delayed or inadequate treatment. This lack of awareness also extends to healthcare providers, impacting their ability to offer comprehensive guidance and support to patients dealing with androgenetic alopecia. In the market, a significant challenge is the lack of awareness among the general population regarding available solutions and their effectiveness.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the Androgenetic Alopecia Treatment market. Due to lockdowns and restrictions, many clinics offering hair loss treatments faced closures or reduced capacity, leading to a decline in patient visits and treatment procedures. Supply chain disruptions also affected the availability of hair loss medications and therapies. However, the market has shown resilience with the adoption of telemedicine for consultations and the gradual recovery of healthcare services post-pandemic.

The hair transplantation segment is expected to be the largest during the forecast period

The hair transplantation segment is expected to be the largest during the forecast period. In the market for this treatment, advancements in technology and techniques have significantly improved outcomes and patient satisfaction. The demand for hair transplantation procedures continues to rise, driven by factors such as increasing awareness, improved affordability, and the desire for a more natural appearance. This trend is expected to persist as more individuals seek effective solutions for hair loss.

The dermatology clinics segment is expected to have the highest CAGR during the forecast period

The dermatology clinics segment is expected to have the highest CAGR during the forecast period. These clinics employ dermatologists who diagnose and prescribe personalized treatments such as topical medications, oral medications, and advanced procedures like PRP therapy or hair transplants. They also provide comprehensive consultations and ongoing monitoring to address the unique needs of each patient, contributing significantly to the growing market for the treatments.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Technological advancements in the field of hair restoration, such as laser therapy devices and stem cell treatments, contribute to the growth of the market as patients seek more effective and minimally invasive solutions. The market is competitive, with pharmaceutical companies, medical device manufacturers, and specialized clinics vying for market share by offering innovative products and services.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period driven by factors such as increasing awareness about hair loss treatments, advancements in medical technologies, and rising disposable incomes. Countries like India, China, and Japan are witnessing a surge in demand for hair loss solutions, including medications, therapies, and surgical procedures. Key players in the market are focusing on developing innovative products to cater to this growing demand and enhance their market presence in the region.

Key players in the market

Some of the key players in Androgenetic Alopecia Treatment market include Merck & Co., Inc., Johnson & Johnson, Pfizer Inc., Bayer AG, GlaxoSmithKline, Allergan, Histogen Inc., Dr. Reddy's Laboratories, Cipla Limited, Aclaris Therapeutics, Anterios, Inc., Aurora Scalp Clinics, Shiseido, Histogenics Corporation, Regenera Activa and Sun Pharmaceutical Industries Ltd.

Key Developments:

In December 2023, Sun Pharmaceutical Industries Ltd. entered into a strategic collaboration with Aclaris. Sun Pharma will get exclusive rights for the use of deuruxolitinib JAK inhibitor or other isotopic forms of ruxolitinib used to treat alopecia areata and androgenetic alopecia

In June 2023, Dr. Reddy's Laboratories Ltd. announced an expansion of its generics business in India with the launch of RgenX. This dedicated division offers a wider range of affordable products to patients

In June 2023, Pfizer, Inc. received the U.S. FDA approval of Litfulo (ritlecitinib) to treat hair loss caused by alopecia. The drug blocks inflammatory signals that increase hair loss

Treatment Types Covered:

• Topical Treatments
• Oral Medications
• Hair Transplantation
• Low-Level Laser Therapy (LLLT)
• Other Treatment Types

Medication Types Covered:

• 5-alpha Reductase Inhibitors (5ARIs)
• Minoxidil
• Finasteride
• Dutasteride
• Other Medication Types

Route of Administrations Covered:

• Topical Solutions
• Injectable Treatments
• Oral
• Implants

Distribution Channels Covered:

• Drug Stores
• Online Retail
• Specialty Clinics
• Hospitals

End Users Covered:

• Homecare Settings
• Dermatology Clinics
• Pharmaceutical
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Androgenetic Alopecia Treatment Market, By Treatment Type

• 5.1 Introduction
• 5.2 Topical Treatments
• 5.3 Oral Medications
• 5.4 Hair Transplantation
• 5.5 Low-Level Laser Therapy (LLLT)
• 5.6 Other Treatment Types

6 Global Androgenetic Alopecia Treatment Market, By Medication Type

• 6.1 Introduction
• 6.2 5-alpha Reductase Inhibitors (5ARIs)
• 6.3 Minoxidil
• 6.4 Finasteride
• 6.5 Dutasteride
• 6.6 Other Medication Types

7 Global Androgenetic Alopecia Treatment Market, By Route of Administration

• 7.1 Introduction
• 7.2 Topical Solutions
• 7.3 Injectable Treatments
• 7.4 Oral
• 7.5 Implants

8 Global Androgenetic Alopecia Treatment Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Drug Stores
• 8.3 Online Retail
• 8.4 Specialty Clinics
• 8.5 Hospitals

9 Global Androgenetic Alopecia Treatment Market, By End User

• 9.1 Introduction
• 9.2 Homecare Settings
• 9.3 Dermatology Clinics
• 9.4 Pharmaceutical
• 9.5 Other End Users

10 Global Androgenetic Alopecia Treatment Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Merck & Co., Inc.
• 12.2 Johnson & Johnson
• 12.3 Pfizer Inc.
• 12.4 Bayer AG
• 12.5 GlaxoSmithKline
• 12.6 Allergan
• 12.7 Histogen Inc.
• 12.8 Dr. Reddy's Laboratories
• 12.9 Cipla Limited
• 12.10 Aclaris Therapeutics
• 12.11 Anterios, Inc.
• 12.12 Aurora Scalp Clinics
• 12.13 Shiseido
• 12.14 Histogenics Corporation
• 12.15 Regenera Activa
• 12.16 Sun Pharmaceutical Industries Ltd.